CTN :45415921
30 Jun, 2026
NA
Tender For e-tender for procurement of drug items under table-a, for two years from the date of aoc. - amoxicillin trihydrate dispersible tabs. i.p 125mg, amoxycillin 250 mg + cloxacillin 250mg capsule., atropine sulphate inj. i.p. 0.6 mg/ml-1ml amp., azacitidine inj 100 mg /vial, azathioprine 50 mg tab., benzyl benzoate application i.p 25% w/w-500 ml bot., bimatoprost eye drop 0.03%, bupivacaine 0.5% inj - 20ml vial, cabergoline tab 0.5mg, caffeine citrate 1 ml inj per vial/amp, carmustine inj. 100mg/vial, cefotaxime sodium inj. i.p. 125 mg.vial., ceftazidime inj. 1gm./vial, cetuximab inj. 100mg( 5mg/ml) / - 20ml vial, cetuximab inj. 500 mg (5mg/ml)/100ml vial, cilostazol tab ip 50 mg, clopidogrel 75mg tab., daclatasvir 60 mg tab., decitabine inj 50 mg, deferasirox 250mg dispersable tab., desflurence inhalation agent 240 ml, dexamethasone 4 mg tab., dexamethasone tab. i.p. 0.5 mg, diclofenac sod. 50 mg tab., diclofenac sodium injection i.p. 25mg/ml- 3ml amps, digoxin tablet i.p. 0.25 mg, dorzolamide hydrochloride 2.0% eye drop in 5ml, fexofenadine tab 120 mg, fibrin sealent with fast & slow setting of thrombin 1ml, fludarabine inj. - 50mg / 5ml, flurourocil inj. i.p. 250mg. in 5ml. amp., fluticasone nasal spray ip 50 mcg (in maximum of 120 mdi pack), furosemide inj. i.p 20mg/2ml. ampoule, halazone tablet for solution u.s.p. 4mg, human an cl
ass="text-red-selected">hep
atitisan> b immunoglobulin inj. 200 iu volume in 0.5 ml or 1 ml vi
al/pfs, ibrutinib 140 mg c
ap., inflixim
ab inj. 100mg/vi
al, isosorbide-5-mononitr
ate 20 mg, isosorbide-dinitr
ate t
ab i.p. 5mg., ivermectin 6mg t
ab., leuprolide depot inj. 22.5 mg/vi
al, levetir
acet
am inj. 100 mg /ml in 5ml
amps, levoflox
acin 500 mg t
ab., levos
albut
amol 1.25 mg + ipr
atropium bromide 500mcg respules, levos
albut
amol or
al suspension 1mg/5ml, linezolid infusion 600 mg / 300ml, linezolid syrup 100mg / 5ml, melph
al
an hcl inj. 50 mg (powder), methotrex
ate t
ab 15 mg, n
aproxen 250mg t
ab., neostigmine methylsulph
ate inj.i.p. 0.5mg/ ml - 1ml
ampoule, nicor
andil t
abs 5mg, ond
ansetron inj. 2mg/ ml in 2ml
amp., penicill
amine 250 mg. c
ap., plerix
afor inj 24mg/1.2ml per vi
al, polymixin b sulf
ate inj. 5,00,000 units/vi
al, pom
alidomide 2mg t
ab / c
ap, prednisolone t
ab.20mg., pyr
azin
amide t
ab. i.p. 500mg, pyridostigmine t
ab 30 mg, risperidone t
ab. 2 mg, s
acubitril + v
als
art
an t
ab. 50mg, sodium chloride inj 0.45% in polypropelene bottle in ffs technology, sodium fusid
ate cre
am / ointment 2%, solifen
acin 5mg t
ab., succinyl
ated polygelline, sulf
as
al
azine t
ab 500 mg, teicopl
anin inj. 200 mg /vi
al, tet
anus toxoid inj. (
absorbed) 0.5ml
amp. single dose, thi
amine 100 mg. inj. per 2ml
ampule, tinid
azole t
ab ip 500 mg, tropic
amide 0.8% with phenylephrine hydrochloride 5% eye drop, v
aleth
am
ate bromide inj 8 mg/ml in 1ml
amp., vecuronium bromide inj. 2mg /ml 2ml vi
al, import
ant note: 1.
all prospective bidders
are requested to quote the r
ate in boq
as per
accounting unit &
amp; item specific
ation
as mentioned in the t
able-
a. wrong quoting of the r
ate in boq will be de
alt with
as per pen
al provisions of the t&
amp;c of the tender.2. tendered qu
antity is just
a tent
ative qu
antity
and should not be tre
ated
as fin
al. it m
ay incre
ase or decre
ase,
as per need of the st
ate. keeping this in mind, the supplier is not
allowed to seek termin
ation of the r
ate contr
act
after finishing supply of tendered qu
antity.3. qu
ality of the product supplied, m
ay be
ascert
ained by testing / physic
al ex
amin
ation by the experts
at
any st
age of the tender period.4. the prospective bidders of the s
aid tender
are requested to m
ake
a decl
ar
ation in
affid
avit under
annexure vi(b) in c
ase of sole m
anuf
acturer/importer (i.e. propriet
ary in n
ature).5. if the item(s) under sole m
anuf
acturer / importer is (
are) propriet
ary in n
ature, qu
arterly intim
ation is solicited from the
approved bidders positively reg
arding the st
atus of their item(s) propriet
ary in n
ature, otherwise their item(s) will be blocked in the smis.6. in c
ase of tie bid, decision will be t
aken by the ti
a as per g.o. no. 2320-f